Passage Bio (Nasdaq:PASG) - Aandelenkoers, Nieuws & Analyse

PASG Overzicht aandelen

Passage Bio, Inc., een bedrijf dat genetische geneesmiddelen produceert, ontwikkelt gentherapieën voor ziekten van het centrale zenuwstelsel.

Over het bedrijf

PASG fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $38M )

+ 1 meer risico

Passage Bio, Inc. Concurrenten

NextCure

NasdaqGS:NXTC

US$36.6m

Achilles Therapeutics

NasdaqGS:ACHL

US$42.5m

LakeShore Biopharma

NasdaqCM:LSB

US$41.0m

Carisma Therapeutics

NasdaqGM:CARM

US$45.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Passage Bio
Historische aandelenkoersen
Huidige aandelenkoers	US$0.65
52 Week Hoogtepunt	US$1.79
52 Week Laag	US$0.54
Bèta	1.19
11 maand verandering	7.82%
3 maanden verandering	-16.92%
1 Jaar Verandering	-6.90%
33 jaar verandering	-92.34%
5 jaar verandering	n/a
Verandering sinds IPO	-97.08%

Recent nieuws en updates

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Sep 24

Recent updates

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Rendement voor aandeelhouders

	PASG	US Biotechs	US Markt
7D	3.9%	1.6%	2.3%
1Y	-6.9%	23.6%	35.1%

Rendement versus industrie: PASG presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 23.6 % opleverde.

Rendement versus markt: PASG presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 35.1 % opleverde.

Prijsvolatiliteit

Is PASG's price volatile compared to industry and market?
PASG volatility
PASG Average Weekly Movement	11.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van PASG is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van PASG is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	58	Will Chou	www.passagebio.com

Passage Bio, Inc., een bedrijf gespecialiseerd in genetische geneesmiddelen, ontwikkelt gentherapieën voor ziekten van het centrale zenuwstelsel. Het ontwikkelt PBGM01, een functioneel GLB1-gen dat codeert voor ß-galactosidase voor infantiele GM1; PBFT02, een functioneel granuline (GRN) en gen dat codeert voor progranuline (PGRN) voor de behandeling van FTD veroorzaakt door progranuline-deficiëntie; en PBKR03, een functioneel GALC-gen dat codeert voor het hydrolytische enzym galactosylceramidase voor infantiele Krabbeziekte. Het bedrijf ontwikkelt PBML04 voor de behandeling van metachromatische leukodystrofie; PBAL05 voor de behandeling van amyotrofische laterale sclerose; en een ander programma voor de ziekte van Huntington.

Passage Bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Passage Bio zich tot de beurswaarde?
PASG fundamentele statistieken
Marktkapitalisatie	US$38.39m
Inkomsten(TTM)	-US$76.57m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is PASG overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PASG resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$76.57m
Inkomsten	-US$76.57m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.24
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PASG op de lange termijn?

Bekijk historische prestaties en vergelijking

PASG Overzicht aandelen

Beloningen

Risicoanalyse

Passage Bio, Inc. Concurrenten

NasdaqGS:NXTC

US$36.6m

NasdaqGS:ACHL

US$42.5m

NasdaqCM:LSB

US$41.0m

NasdaqGM:CARM

US$45.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Recent updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting